New Multiple Myeloma Staging Systems Outperform the Standard New Multiple Myeloma Staging Systems Outperform the Standard
Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Robust Score Can ID Infection Risk in Newly Diagnosed Multiple Myeloma
TUESDAY, Dec. 19, 2023 -- A robust score can identify patients with newly diagnosed multiple myeloma (NDMM) at risk for severe infection/death, according to a study published online Dec. 7 in Leukemia.
Elias K. Mai, M.D., from the University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 19, 2023 Category: Pharmaceuticals Source Type: news
Six little-known warning signs of multiple myeloma after death of Max Payne actor James McCaffery
The 65-year-old US actor was reportedly diagnosed with multiple myeloma, which arises from plasma cells within bone marrow - the 'spongy' substance lurking within bones. (Source: the Mail online | Health)
Source: the Mail online | Health - December 19, 2023 Category: Consumer Health News Source Type: news
Alan Wake 2, Max Payne actor James McCaffrey dead at 65
James McCaffrey, the voice of Max Payne, died Sunday at 65, TMZ reports. A representative for McCaffrey told the publication that the actor, who is known for roles across Control and the Max Payne and Alan Wake franchises, died of multiple myeloma, and that he was surrounded by friends and family…#jamesmccaffrey #maxpayne #tmz #mccaffrey #alanwake #dickwolfs #actorsstudio #remedyentertainments #finnish #rockstarstudios (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2023 Category: Consumer Health News Source Type: news
James McCaffrey, ‘Max Payne’ and ‘Alan Wake 2’ Voice Actor, Dies at 65
James McCaffrey, an actor who provided the voice of Max Payne in the popular video game series and most recently voiced Alex Casey in “Alan Wake 2,” died Sunday after a battle with cancer, Variety has confirmed with his manager. He was 65. McCaffrey was diagnosed with multiple myeloma, according…#jamesmccaffrey #maxpayne #alexcasey #variety #tmz #newyorkundercover #arthurobyrne #viper #mccaffrey #jamesxavier (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2023 Category: Consumer Health News Source Type: news
Why Some Myeloma Patients Refuse Stem Cell Transplant
(MedPage Today) -- A real-world analysis presented at the American Society of Hematology annual meeting showed that the refusal rate for autologous hematopoietic stem cell transplantation among patients with multiple myeloma is low, at about 2... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 15, 2023 Category: Hematology Source Type: news
This Frontline Therapy Is Better in Multiple Myeloma: Study This Frontline Therapy Is Better in Multiple Myeloma: Study
A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
No Benefit to Salvage Transplant in R/R Multiple Myeloma No Benefit to Salvage Transplant in R/R Multiple Myeloma
Long-term follow-up shows no progression-free or overall survival advantage among patients who received salvage transplant vs continuous lenalidomide plus dexamethasone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
WEDNESDAY, Dec. 13, 2023 -- For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 13, 2023 Category: Pharmaceuticals Source Type: news
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma
(MedPage Today) -- SAN DIEGO -- Patients with newly diagnosed multiple myeloma had almost a 60% improvement in progression-free survival (PFS) if they received the anti-CD38 daratumumab (Darzalex) in addition to standard therapy, a large randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 13, 2023 Category: Hematology Source Type: news
Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity
' This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations. 'MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies
CAR T cells directed against the B-cell maturation antigen (BCMA) are linked to systemic and neurological side effects, while the antibody teclistamab is associated with increased infection risk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Friday, Arcellx Inc ACLX announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or refractory multiple myeloma. The interim anito-cel Phase 1 clinical results (October 15, 2023 cutoff date) demonstrate deep and…#arcellxincaclx #phase1 #median #williamblair #aclx (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2023 Category: Consumer Health News Source Type: news
Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials
(MedPage Today) -- SAN DIEGO -- Multiple myeloma patients in the clinic appear to benefit far less from standard treatments when compared with how the same regimens performed in randomized controlled trials (RCTs), according to a retrospective... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 10, 2023 Category: American Health Source Type: news
New Hybrid Treatment Forces Cancer Cells to Starve
NEW YORK, Dec. 9, 2023 /PRNewswire/ -- The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows. The work addressed multiple myeloma, a cancer that forms in blood cells that normally fight infections by making proteins that... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
